A Pilot Study of DKN-01 and Lenalidomide (Revlimid)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2017
At a glance
- Drugs DKN 01 (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors HealthCare Pharmaceuticals Inc; Leap Therapeutics
- 01 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 31 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 May 2013 Planned initiation date changed from 1 Jun 2013 to 1 May 2013 as reported by ClinicalTrials.gov.